Emmessar Biotech & Nutrition Ltd
Fundamental Score
Emmessar Biotech & Nutrition Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of EMMESSA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Balanced Promoter Holding (59.53%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
14 factors identified
Below-Average Return on Equity (4.23%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Margin Pressure Concerns (-29.14%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Premium Valuation Risk (P/E: 69.37x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-60.71%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-73.53%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-29.08% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-19.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-19.73% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Limited Institutional Interest (FII+DII: 0.19%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Emmessar Biotech & Nutrition Ltd
About EMMESSA
Business Overview
Emmessar Biotech & Nutrition Limited, a healthcare company, provides healthcare and nutritional products in India and internationally. The company operates through Healthcare and Rent on Lease Land segments. It also offers CalmCream, a multi-functional skin cream; Calm Cream RESQ, a skin cream used for burns from sun, radiation, heat and chemicals; Cute-N-Comely, a cosmetic skin cream; MagiCream, a cream used for post-surgical scars; and Muscle Flex Gel, a gel used to relieve pain from aching muscles. In addition, the company offers vedaceuticals, an ayurveda disease curing medicine. Further, it provides healthcare products for dermatology, osteoporosis, anti-ageing, physical ailments, and burns, including radiation. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was incorporated in 1992 and is based in Mumbai, India.
Company Details
Key Leadership
EMMESSA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Emmessar Biotech & Nutrition Ltd (EMMESSA)?
As of 29 Jan 2026, 10:38 am IST, Emmessar Biotech & Nutrition Ltd (EMMESSA) is currently trading at ₹25.99. The stock has a market capitalization of ₹15.95 (Cr).
Is EMMESSA share price Overvalued or Undervalued?
EMMESSA is currently trading at a P/E ratio of 69.37x, compared to the industry average of 20.98x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Emmessar Biotech & Nutrition Ltd share price?
Key factors influencing EMMESSA's price include its quarterly earnings growth (Sales Growth: -73.53%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Emmessar Biotech & Nutrition Ltd a good stock for long-term investment?
Emmessar Biotech & Nutrition Ltd shows a 5-year Profit Growth of -19.73% and an ROE of 4.23%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Emmessar Biotech & Nutrition Ltd compare with its industry peers?
Emmessar Biotech & Nutrition Ltd competes with major peers in the Commodity Chemicals. Investors should compare EMMESSA's P/E of 69.37x and ROE of 4.23% against the industry averages to determine its competitive standing.
What is the P/E ratio of EMMESSA and what does it mean?
EMMESSA has a P/E ratio of 69.37x compared to the industry average of 20.98x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹69 for every ₹1 of annual earnings.
How is EMMESSA performing according to Bull Run's analysis?
EMMESSA has a Bull Run fundamental score of 15.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does EMMESSA belong to?
EMMESSA operates in the Commodity Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Emmessar Biotech & Nutrition Ltd.
What is Return on Equity (ROE) and why is it important for EMMESSA?
EMMESSA has an ROE of 4.23%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Emmessar Biotech & Nutrition Ltd generates profits from shareholders' equity.
How is EMMESSA's debt-to-equity ratio and what does it indicate?
EMMESSA has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is EMMESSA's dividend yield and is it a good dividend stock?
EMMESSA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has EMMESSA grown over the past 5 years?
EMMESSA has achieved 5-year growth rates of: Sales Growth -29.08%, Profit Growth -19.73%, and EPS Growth -19.73%.
What is the promoter holding in EMMESSA and why does it matter?
Promoters hold 59.53% of EMMESSA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is EMMESSA's market capitalization category?
EMMESSA has a market capitalization of ₹16 crores, placing it in the Small-cap category.
How volatile is EMMESSA stock?
EMMESSA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for EMMESSA?
EMMESSA has a 52-week high of ₹N/A and low of ₹N/A.
What is EMMESSA's operating profit margin trend?
EMMESSA has a 5-year average Operating Profit Margin (OPM) of -29.14%, indicating the company's operational efficiency.
How is EMMESSA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -73.53% and YoY Profit Growth of -60.71%.
What is the institutional holding pattern in EMMESSA?
EMMESSA has FII holding of 0.00% and DII holding of 0.19%. Significant institutional holding often suggests professional confidence in the stock.